The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.

More than 50 insurers have pledged to streamline and simplify the prior authorization process through six new commitments.

Bullous pemphigoid (BP) is an acquired disease that belongs to the group of autoimmune subepidermic bullous disorders. It features circulating autoantibodies against distinctive skin's basal membrane ...